Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|ClinicalTrials.gov Identifier: NCT00153075|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : October 29, 2013
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Disease, Chronic Obstructive Asthma||Device: Berodual Respimat Device: Berodual HFA-MDI||Phase 4|
This is a single dose, randomised, active-controlled, six period, open-label cross-over trial in adult patients with COPD.
Berodual (fenoterol hydrobromide 50 g + ipratropium bromide 20 g) will be delivered via the Respimat inhaler and the MDI at 3 different inspiratory flow rates: 15 L/min, 30 L/min and 90 L/min. The optimal flow rate is expected to be 30 L/min for both inhalers.
On each test day patients will practise the inhalation manoeuvre with either a placebo Respimat or MDI inhaler. When patients can perform the inhalation technique correctly and they can obtain the required inspiratory flow rates the placebo will be replaced with the radio-labelled formulation.
The primary analysis will be carried out using the Sign Test. This is a non-parametric analysis in which no assumptions are made about the shape of the distribution of the responses from the Respimat inhaler and from the MDI under the null hypothesis.
The null hypothesis is that flow rate has the same effect on the Respimat and MDI inhalers. The alternative hypothesis is that flow rate has a different effect on the Respimat inhaler than on the MDI inhaler.
This means that under the null hypothesis the median of the differences between the Respimat inhaler and MDI pairs is zero i.e., the differences are equally lik ely to be positive or negative. Under the alternative hypothesis the median of the differences between the Respimat inhaler and MDI pairs is not zero i.e., the frequencies of the positive and negative signs are different.
For the primary comparison the whole lung deposition achieved for each patient at the 90 L/min flow rate will be expressed as a percentage of the whole lung deposition achieved by that patient at the 30 L/min flow rate for the Respimat and MDI inhalers separately. The difference between each pair of observations ((Respimat 90 L/min / Respimat 30 L/min) - (MDI 90 L/min / MDI 30 L/min)) will then be calculated and the sign of the direction of the difference noted i.e., positive or negative. The probability associated with the occurrence of the observed number of positive and negative differences will then be determined by reference to the binomial distribution with the probability of a positive or negative difference equal to 0.5 under the null hypothesis. If the alternative hypothesis is, however, true and flow rate does in fact have less effect on the Respimat inhaler than on the MDI inhaler, then there is likely to be a statistically significant greater number of positive differences.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||19 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomised Open Label, Six Way, Cross-over Scintigraphic Evaluation of the Effect of Inspiratory Flow Rate on Lung and Oropharyngeal Deposition With the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD).|
|Study Start Date :||September 2005|
|Actual Primary Completion Date :||December 2005|
|Study Completion Date :||December 2005|
- Whole lung deposition [ Time Frame: 12 weeks ]
- Central lung zone deposition [ Time Frame: 12 weeks ]
- Intermediate lung zone deposition [ Time Frame: 10 weeks ]
- Peripheral lung zone deposition [ Time Frame: 12 weeks ]
- Ratio of peripheral to central zone deposition [ Time Frame: 12 weeks ]
- Oropharyngeal deposition [ Time Frame: 12 weeks ]
- Device deposition and exhaled air filter deposition [ Time Frame: 12 weeks ]
- FEV1 15, 30 and 60 minutes post-administration (safety only) [ Time Frame: 12 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00153075
|Inamed Research GmbH & Co. KG|
|Gauting, Germany, 82131|
|Study Chair:||Boehringer Ingelheim Study Coordinator||B.I. Pharma GmbH & Co. KG|